Drug Profile

BAX 555

Alternative Names: 5-HMF - AesRx; 5-hydroxymethyl furfural; Aes-103

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Virginia Commonwealth University
Developer AesRx; National Institutes of Health (USA); Takeda
Class Antianaemics; Small molecules
Mechanism of Action Haemoglobin stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Sickle cell anaemia
New Molecular Entity Yes

Highest Development Phases

No development reported Sickle cell anaemia

Most Recent Events

19 Dec 2019 No development reported - Phase-II for Sickle cell anaemia in United Kingdom (PO)
08 Jan 2019 Shire has been acquired and merged into Takeda
03 Jun 2016 Baxalta has been acquired and merged into Shire

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com